Table 3.
Base case analysis results
| Health outcomes | MiniMed 780G | isCGM plus MDI or CSII | Difference |
|---|---|---|---|
| Discounted life expectancy, years | 19.27 (0.20) | 19.11 (0.19) | + 0.16 |
| Discounted quality-adjusted life expectancy, QALYs | 14.25 (0.15) | 12.31 (0.13) | + 1.95 |
| Discounted direct costs, SEK | 2,593,226 (58,912) | 1,754,941 (59,956) | + 838,285 |
| Discounted direct costs, EUR | 259,323 (5,891) | 175,494 (5,996) | + 83,829 |
| Discounted combined costs, SEK | 3,414,589 (95,866) | 2,687,181 (95,819) | + 727,408 |
| Discounted combined costs, EUR | 341,459 (9,587) | 268,718 (9,582) | + 72,741 |
| ICER based on direct costs | SEK 430,663 per QALY gained | ||
| ICER based on combined costs | SEK 373,700 per QALY gained | ||
Values are means (standard deviations)
CSII continuous subcutaneous insulin infusion, EUR euros, ICER incremental cost-effectiveness ratio, isCGM intermittently scanned continuous glucose monitor, MDI self-injection of multiple daily insulin doses, QALYs quality-adjusted life years, SEK Swedish krona